Here, we present Bcl9@TP, a self-assembling peptide nanoprodrug that selectively disrupts the β-catenin/BCL9 interaction in CRC, delivering direct antitumor activity while augmenting responses to immunotherapy. The gene discussed is BCL9; the disease is colorectal carcinoma.